Lead Product(s): TY027
Therapeutic Area: Infections and Infectious Diseases Product Name: TY027
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
Results of Phase 1 clinical trials showed no serious adverse events with infusion of TY027 in healthy volunteers, and researchers evaluated up to the 30 mg/kg dose.